References
- Cavo M, Galli M, Pantani L et al. Bortezomib-thalidomide-dexamethasone incorporated into autotranplantation is associated with more favorable outcomes after relapse in comparison with thalidomide-dexamethasone plus autotranplantation in multiple myeloma. Blood 2012;120(Suppl. 1): Abstract 4210.
- Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205–212.
- Lentzsch S, O’Sullivan A, Kennedy R, et al. Combination of bendamustine, lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma is safe an highly effective:results of phase I/II open-label, dose escalation study. Blood 2011;118(Suppl. 1): Abstract 304.
- Ponisch W, Bourgeois M, Wang S-Y et al. Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma. Blood 2007;110(Suppl. 1): Abstract 2723.
- Berdeja JG, Couriel DR, Murphy P, et al. A phase II trial of combined bendamustine, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for high-dose chemotherapy: results of a planned interim safety analysis. Blood 2011;118(Suppl. 1): Abstract 2943.
- Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287–1288.
- Cheson BD, Wendtner CM, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas and multiple myeloma:treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21–27.